Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Main Authors: | Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Shlomo Flechter, Rina Falb, Michael Gurevich |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-05-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864211020082 |
Similar Items
-
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
by: Anat Achiron, et al.
Published: (2021-04-01) -
Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.
by: Anat Achiron, et al.
Published: (2012-01-01) -
Cognitive function in multiple sclerosis: A long-term look on the bright side.
by: Yermi Harel, et al.
Published: (2019-01-01) -
Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways
by: A. Achiron, et al.
Published: (2004-01-01) -
RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice
by: Rina Zilkha-Falb, et al.
Published: (2020-10-01)